Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights
Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027